PMID- 19413703
OWN - NLM
STAT- MEDLINE
DCOM- 20090818
LR  - 20151119
IS  - 1467-789X (Electronic)
IS  - 1467-7881 (Linking)
VI  - 10
IP  - 4
DP  - 2009 Jul
TI  - Plasma phospholipid transfer protein (PLTP): review of an emerging 
      cardiometabolic risk factor.
PG  - 403-11
LID - 10.1111/j.1467-789X.2009.00586.x [doi]
AB  - Plasma phospholipid transfer protein (PLTP) is a lipid transfer glycoprotein that 
      binds to and transfers a number of amphipathic compounds. In earlier studies, the 
      attention of the scientific community focused on the positive role of PLTP in 
      high-density lipoprotein (HDL) metabolism. However, this potentially 
      anti-atherogenic role of PLTP has been challenged recently by another picture: 
      PLTP arose as a pro-atherogenic factor through its ability to increase the 
      production of apolipoprotein B-containing lipoproteins, to decrease their 
      antioxidative protection and to trigger inflammation. In humans, PLTP has mostly 
      been studied in patients with cardiometabolic disorders. Both PLTP and related 
      cholesteryl ester transfer protein (CETP) are secreted proteins, and adipose 
      tissue is an important contributor to the systemic pools of these two proteins. 
      Coincidently, high levels of PLTP and CETP have been found in the plasma of obese 
      patients. PLTP activity and mass have been reported to be abnormally elevated in 
      type 2 diabetes mellitus (T2DM) and insulin-resistant states, and this elevation 
      is frequently associated with hypertriglyceridemia and obesity. This review 
      article presents the state of knowledge on the implication of PLTP in lipoprotein 
      metabolism, on its atherogenic potential, and the complexity of its implication 
      in obesity, insulin resistance and T2DM.
FAU - Tzotzas, T
AU  - Tzotzas T
AD  - Department of Nutrition and Dietetics, Technological Educational Institution, 
      Thessaloniki, Greece. tzotzas@otenet.gr
FAU - Desrumaux, C
AU  - Desrumaux C
FAU - Lagrost, L
AU  - Lagrost L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090421
PL  - England
TA  - Obes Rev
JT  - Obesity reviews : an official journal of the International Association for the 
      Study of Obesity
JID - 100897395
RN  - 0 (Apolipoproteins B)
RN  - 0 (Biomarkers)
RN  - 0 (CETP protein, human)
RN  - 0 (Cholesterol Ester Transfer Proteins)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Phospholipid Transfer Proteins)
SB  - IM
MH  - Adipose Tissue/metabolism
MH  - Apolipoproteins B/metabolism
MH  - Biological Transport/physiology
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/*blood/epidemiology/metabolism
MH  - Cholesterol Ester Transfer Proteins/*metabolism
MH  - Diabetes Mellitus, Type 2/*blood/epidemiology/metabolism
MH  - Humans
MH  - Insulin Resistance
MH  - Lipoproteins, HDL/*blood
MH  - Obesity/*blood/epidemiology/metabolism
MH  - Phospholipid Transfer Proteins/*blood
MH  - Risk Factors
RF  - 68
EDAT- 2009/05/06 09:00
MHDA- 2009/08/19 09:00
CRDT- 2009/05/06 09:00
PHST- 2009/05/06 09:00 [entrez]
PHST- 2009/05/06 09:00 [pubmed]
PHST- 2009/08/19 09:00 [medline]
AID - OBR586 [pii]
AID - 10.1111/j.1467-789X.2009.00586.x [doi]
PST - ppublish
SO  - Obes Rev. 2009 Jul;10(4):403-11. doi: 10.1111/j.1467-789X.2009.00586.x. Epub 2009 
      Apr 21.